# RNN 2nd Gen Model Varian Medical Systems, Inc. Electromedical equipment

Stock predictor AI models:
Subscribe >> Deal exit on
May 29, 2020
Deal entry on
May 29, 2020
8.15%Expected margin
68.75% successful of 32 deals
$ 121.39 Last close price
at 29-may-2020

VAR

Model's trade recommendations -3.10% Return for period

1.13% Annual return

$10.61B Market Cap

β 0.85  

VAR

Model (following trade recommendations)

VAR

Underlying stock

S&P 500

Index
Return for period -3.10%
9.00%
1.78%
52wk return 3.28%
-3.86%
16.82%
52wk Range
89.81—149.57
2000.54—2399.63
Sortino ratio 0.16
Sharpe ratio 0.13
Norm. RMSE 4.33%
Downside risk 12.54%
Volatility 0.00%
  • HOLD Analysts consensus recommendation

Varian Medical Systems, Inc. is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. It supplies tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems, Inc. is headquartered in Palo Alto, California.

Industry sector: Medical

Sector classification: Electromedical equipment

Deep Learning based analysis and prediction model for Varian Medical Systems, Inc. (VAR) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for VAR model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for VAR.

Model is being retrained on a regular basis.

-->
Float 91M
P/E 26.78
Shares Outstanding 91M
% Held by Insiders 0.78%
% Held by Institutions 98.88%
EPS (last reported FY) $3.60
EPS (last reported Q) $1.15
EPS, estimated (last reported Q) $1.06
Total revenues $3 B
Net income $0 B